Project description
To improve the treatment of non-alcoholic fatty liver disease depending on the presence of coronary heart disease by correcting the bacteriological composition of the intestinal microbiota. The planned study aims to clarify the role of the intestinal microbiota in the formation of fatty liver and atherogenesis in patients with a comorbid course of non-alcoholic fatty liver disease and coronary heart disease.
The effect of combination treatment with an additional probiotic containing a strain Bifidobacterium infantis 35624 of 1 capsule per day for 4 weeks will be investigated in comparison with standard therapy regimens for the course of non-alcoholic fatty liver disease without clinical signs of coronary heart disease and in combination with them. The results of the study will be incorporated into the clinical work of medical establishments, consumers can become doctors therapists and gastroenterologists of inpatient departments and outpatient clinics of regional and republican levels.
Ukraine's winning projects
